A detailed history of Iht Wealth Management, LLC transactions in Vaxart, Inc. stock. As of the latest transaction made, Iht Wealth Management, LLC holds 225,616 shares of VXRT stock, worth $139,881. This represents 0.01% of its overall portfolio holdings.

Number of Shares
225,616
Previous 234,716 3.88%
Holding current value
$139,881
Previous $157,000 21.66%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.58 - $0.99 $5,278 - $9,009
-9,100 Reduced 3.88%
225,616 $191,000
Q2 2024

Aug 14, 2024

SELL
$0.53 - $1.3 $1,010 - $2,479
-1,907 Reduced 0.81%
234,716 $157,000
Q1 2024

May 15, 2024

SELL
$0.56 - $1.41 $529 - $1,332
-945 Reduced 0.4%
236,623 $307,000
Q4 2023

Feb 14, 2024

SELL
$0.57 - $0.85 $10,477 - $15,624
-18,382 Reduced 7.18%
237,568 $135,000
Q3 2023

Nov 14, 2023

SELL
$0.69 - $0.85 $812 - $1,001
-1,178 Reduced 0.46%
255,950 $191,000
Q2 2023

Aug 14, 2023

SELL
$0.6 - $1.41 $2,457 - $5,773
-4,095 Reduced 1.57%
257,128 $187,000
Q1 2023

May 15, 2023

SELL
$0.71 - $1.25 $5,427 - $9,555
-7,644 Reduced 2.84%
261,223 $198,000
Q4 2022

Feb 14, 2023

SELL
$0.75 - $2.24 $1,093 - $3,265
-1,458 Reduced 0.54%
268,867 $258,000
Q3 2022

Nov 22, 2022

BUY
$2.09 - $4.5 $22,041 - $47,457
10,546 Added 4.06%
270,325 $589,000
Q2 2022

Aug 15, 2022

BUY
$2.7 - $5.28 $2,848 - $5,570
1,055 Added 0.41%
259,779 $909,000
Q1 2022

May 16, 2022

BUY
$4.29 - $6.64 $56,083 - $86,804
13,073 Added 5.32%
258,724 $1.3 Million
Q4 2021

Feb 14, 2022

BUY
$5.77 - $7.96 $203,963 - $281,378
35,349 Added 16.81%
245,651 $1.54 Million
Q3 2021

Nov 15, 2021

BUY
$6.67 - $9.8 $19,743 - $29,008
2,960 Added 1.43%
210,302 $1.67 Million
Q2 2021

Aug 16, 2021

BUY
$5.06 - $10.78 $1.05 Million - $2.24 Million
207,342 New
207,342 $1.55 Million

Others Institutions Holding VXRT

About Vaxart, Inc.


  • Ticker VXRT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 126,506,000
  • Market Cap $78.4M
  • Description
  • Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...
More about VXRT
Track This Portfolio

Track Iht Wealth Management, LLC Portfolio

Follow Iht Wealth Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Iht Wealth Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Iht Wealth Management, LLC with notifications on news.